NUVATION BIO INC, a prominent player in the bio-pharmaceutical sector, has recently garnered attention with its strategic initiatives and developments in oncology therapeutics. Based in New York, United States, Nuvation Bio Inc. is dedicated to enhancing patient lives by tackling drug resistance in cancer treatments. The company’s innovative approach is reflected in its diverse pipeline, which includes a next-generation ROS1 inhibitor, a brain-penetrant IDH1 inhibitor, and a drug-drug conjugate program. These advancements underscore Nuvation Bio’s commitment to addressing critical challenges in oncology.
Trading on the New York Stock Exchange, Nuvation Bio Inc. has experienced fluctuations in its stock performance. As of November 10, 2026, the company’s close price stood at $4.29, with a 52-week high of $9.75 recorded on December 21, 2025, and a low of $3.975 on November 5, 2026. Despite these variations, the company maintains a market capitalization of $1.48 billion. However, the price-to-earnings ratio remains negative at -10.82, reflecting the company’s current financial dynamics and investment in research and development.
In a significant move to engage with investors and stakeholders, Nuvation Bio Inc. announced that its founder and chief executive, Dr. David Hung, along with the chief financial officer, will participate in a fireside discussion at the Jefferies Global Healthcare Conference in London on November 17. Scheduled for mid-afternoon GMT, this event will be streamed live on the company’s investor-relations platform, with recordings available for three months. This discussion presents an opportunity for Nuvation Bio to showcase its strategic vision and progress in oncology therapeutics to a global audience.
Founded in 2018 by Dr. David Hung, an industry veteran known for launching a leading prostate-cancer medication, Nuvation Bio Inc. has established a strong presence both in the United States and internationally, with offices in Shanghai. The company’s global reach is further supported by its online platform, accessible at www.panacea.ecor1cap.com , which serves patients worldwide.
As Nuvation Bio Inc. continues to advance its pipeline and engage with the healthcare community, its focus remains on delivering innovative solutions to improve patient outcomes in oncology. The upcoming fireside discussion at the Jefferies Global Healthcare Conference is poised to be a pivotal moment for the company, offering insights into its strategic direction and future prospects in the competitive landscape of bio-pharmaceuticals.
